Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis

Tuesday, November 24, 2009 General News
Email Print This Page Comment
Font : A-A+

Contacts:

Cephalon:

Media:

Investor Relations:

Sheryl Williams

Chip Merritt

610-738-6493 (office)

610-738-6376 (office)

610-457-5257 (cell)

cmerritt@cephalon.com

swilliam@cephalon.com

Ception:

Media: Mike Beyer - Sam Brown Inc.

773-463-4211 (office)

beyer@sambrown.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook